Cited by 79Muscle Physiology and DisordersNutrition and Health in AgingAdipose Tissue and Metabolism

Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents

Gurjar, Anagha Ashok, Kushwaha, Sapana, Chattopadhyay, Sourav, Das, Nabanita, Pal, Subhashis, China, Shyamsundar Pal, Kumar, Harish, Trivedi, Arun Kumar +3 more·2020·Metabolism

Abstract

Background Skeletal muscle atrophy is characterized by muscle wasting with partial or complete functional loss. Skeletal muscle atrophy severely affects the quality of life and currently, there is no available therapy except for spinal muscular atrophy.Objective Drug repositioning is a promising strategy that reduces cost and time due to prior availability of safety and toxicity details. Here we investigated myogenic and anti-atrophy effects of glucagon-like peptide-1 (GLP-1) analog liraglutide.Methods We used several in vitro atrophy models in C2C12 cells and in vivo models in Sprague Dawley rats to study Liraglutide's efficacy. Western blotting was used to assess cAMP-dependent signaling pathways specifically activated by liraglutide. Therapeutic efficacy of liraglutide was investigated by histological analysis of transverse muscle sections followed by morphometry. Myogenic capacity was investigated by immunoblotting for myogenic factors.Results Liraglutide induced myogenesis in C2C12 myoblasts through GLP-1 receptor via a cAMP-dependent complex network of signaling events involving protein kinase A, phosphoinositide 3-kinase/protein kinase B, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase. Liraglutide imparted protection against freeze injury, denervation, and dexamethasone -induced skeletal muscle atrophy and improved muscular function in all these models. In a therapeutic model, liraglutide restored myofibrillar architecture in ovariectomy-induced atrophy. Anti-atrophy actions of liraglutide involved suppression of atrogene expression and enhancement in expression of myogenic factors.Conclusion Liraglutide imparted protection and restored myofibrillar architecture in diverse models of muscle atrophy. Given its potent anti-atrophy, and recently reported osteoanabolic effects, we propose liraglutide's clinical evaluation in skeletal muscle atrophy and musculoskeletal disorders associated with diverse pathologies.

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2019.154044

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Another rodent study showed that GLP1 directly induces myogenesis via a cAMP-dependent signalling network in skeletal muscle.

    “Another study in rodents showed that GLP1 directly induces myogenesis via a complex cAMP-dependent signalling network in skeletal muscle209.”

    From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [209]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., & Sanyal, S.
Affiliations
Central Drug Research Institute (IN)
Corresponding author
Sanyal, Sabyasachi
Venue
Metabolism
Publisher
Elsevier BV
Published
2020-02
Volume
103
Pages
154044
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2992978377
Cited by
79
References
58
Citations by year
2026: 15 · 2025: 25 · 2024: 21 · 2023: 10 · 2022: 7 · 2021: 1
FWCI
0.66
Type
journal article
Language
en
Open access
closed
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University Grants Commission
  • Council of Scientific and Industrial Research, India
  • Department of Biotechnology, Ministry of Science and Technology, India
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
liraglutide, skeletal muscle atrophy, GLP-1 receptor, drug repurposing, myogenesis, cAMP signaling, protein kinase A, PI3K/Akt signaling, MAPK signaling, denervation-induced atrophy, dexamethasone-induced atrophy, frost damage, ovariectomy, atrogenes, myogenic factors
MeSH terms
Liraglutide, Animals, Cells, Cultured, Delayed-Action Preparations, Male, Muscular Atrophy, Rodentia, Rats, Sprague-Dawley, Muscle, Skeletal, Muscle Development, Myoblasts, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review